Drug Retail

FANGZHOU JIANKE

Ark Launches 'AI+ Chronic Disease Service' Solution

Citi Report: Fangzhou Healthtech Turned Profitable in 2025 and Outlined Strategic Plan for 2026

FANGZHOU JIANKE released FY2025 9 Months Earnings on March 19, 2026 (BJT), with actual revenue of HKD 2.728 B and EPS of HKD 0.0098

FANGZHOU JIANKE released FY2025 Q3 earnings on March 19, 2026 (BJT) with actual revenue of HKD 1.111 B and EPS of HKD -0.0002

FANGZHOU JIANKE released FY2025 Q4 earnings on March 19 During-Market (BJT), actual revenue HKD 1.13 B, actual EPS HKD -0.0008

FANGZHOU JIANKE released FY2025 earnings on March 19 During-Market (BJT), actual revenue HKD 3.854 B (forecast HKD 3.724 B), actual EPS HKD 0.0097

FANGZHOU JIANKE to release FY2025 earnings report on March 19 During-Market (BJT), forecast revenue HKD 3.741 B

ArkHealthTech Completes Share Placements and Subscriptions to Raise Funds

Fangzhou Jianke Raises Funds Through Share Placement for AI Chronic Disease Management Platform

Ark Health Express Reports Positive Profit Forecast for 2025, Aiming for Full Profitability

Ark Aikang and Wangshanjiankang Sign Strategic Cooperation, Collaborating to Explore AI-Enabled Chronic Disease Management

Ark Healthcare's AI Model Receives National Certification

Arkmeds Launches 'Xingshi' Model and Partners with Innovent Biologics and Otsuka Pharmaceutical

Fangzhou Jianke and Innovent Biologics Sign Strategic Partnership to Promote Weight Management

Ark Genie and Zhejiang Daito Pharmaceutical Sign Strategic Cooperation Agreement

Ark Health Guest Announces Release of Self-Developed Xingshi Medical Model

FANGZHOU JIANKE released FY2025 Q1 earnings on August 27, 2025 (BJT) with actual revenue of HKD 799.79 M and actual EPS of HKD 0.005

FANGZHOU JIANKE released FY2025 Semi-Annual earnings on August 27 During-Market (BJT), actual revenue HKD 1.617 B, actual EPS HKD 0.0101

FANGZHOU JIANKE released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue HKD 817.37 M, actual EPS HKD 0.0054

FANGZHOU JIANKE FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02661

513120

512010

159929

510660

516610

06086

589720

AI healthcare stocks in the Hong Kong market surged, with Medlive Technologyrising over 9%. Easy Healthand Bio-Thera Solutions-Bboth increased by more than 6.5%, while Ark Healthclimbed over 5%, and MicroPort Roboticssaw an increase of more than 4%.

CoinLive

QINGSONG HEALTH

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

MEDLIVE

BIOCYTOGEN-B

MircroPort Medbot-B

Minsheng Royal CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

AI Healthcare Stocks Surge in Hong Kong Market

Citi has lowered the target price for FANGZHOU JIANKE to HKD 7.5, believing its current value is severely underestimated. It is expected that revenue for the fiscal year 2025 will reach RMB 3.526 billion, with a net profit of RMB 12 million, turning a profit. FANGZHOU plans to focus on talent recruitment, artificial intelligence investment, and expanding medical insurance cooperation in 2026. The rating is "Buy/High Risk."

AASTOCKS

Citi lowers the target price for FANGZHOU JIANKE to 7.5 yuan, stating that its value is severely underestimated

FANGZHOU JIANKE announced its performance for the fiscal year 2025, with revenue of 3.526 billion RMB, an increase of 30.2% year-on-year. It recorded a net profit of 10.86 million RMB, compared to a loss of 855 million RMB in the previous year, turning from loss to profit; earnings per share of 0.01 RMB. No dividend is declared

"Performance" FANGZHOU JIANKE achieved a net profit of 10.86 million RMB for the year, turning a loss into a profit

00700

TCEHY

TCTZF

Fangzhou Inc. (HK:6086) reported a 30.2% revenue increase to RMB3.53 billion in 2025, achieving a net profit of RMB12 million, reversing a loss from 2024. The company saw a 35% rise in average monthly active users to 13.7 million and expanded its network of registered doctors to over 251,000. Fangzhou launched the "XingShi" large language model to enhance clinical decision-making and formed strategic partnerships with major players like Tencent and Novo Nordisk. The current analyst rating for its stock is a Hold with a price target of HK$2.50.

- Fangzhou Inc. reported a strong operational year in 2025, with revenue increasing by 30.2% to RMB3.53 billion and a net profit of RMB12.0 million.  
- Key metrics included a 35% rise in average monthly active users to 13.7 million and the establishment of strategic partnerships with major players like Tencent and Novo Nordisk.  
- The current market cap stands at HK$2.06 billion, and the latest analyst rating for the stock is Hold with a price target of HK$2.50.

Tip Ranks

TENCENT

Tencent

Tencent Holdings Limited

Fangzhou Swings to Profit as Revenue Surges and Digital Health Platform Expands

688658

Fangzhou Inc.has partnered with Youcare Pharmaceutical Group to enhance AI in chronic disease care in China. This collaboration aims to transform chronic disease services by integrating AI with Youcare's pharmaceutical expertise. The focus will be on developing digital systems for better health management in areas like cardiovascular and endocrine diseases, improving patient access to quality care and medicines. The partnership aligns with China's push for digital healthcare solutions.

rttnews

YKYY

Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care

XS LLM has incorporated five smart agents into a closed-loop system that oversees the entire chronic disease management process.

Unusual Whales

XS LLM named a top healthcare model for 2026 in China, integrates 5 agents in chronic disease management cycle.

08103

08059

08018

08429

00328

01939

02865

03696

02668

Hong Kong stock market overview in the past hour Market sentiment seems to be gradually warming up amid recent fluctuations, especially with small-cap stocks and technology stocks performing actively. Capital flows are clearly leaning towards high-growth and thematic stocks, with short-term enthusiasm continuously rising, driving the overall market upward. Stocks with significant gains are concentrated in the video, finance, and health sectors, indicating investors' preference for these areas. Overall, the market pace is fast, with increased volatility and heightened participation from short-term traders. The stock with the largest movement in the past hour is HMVOD, which surged by 76.10%, becoming the market's focus. After a stable performance in the morning session, the stock suddenly accelerated upward, attracting a large influx of capital, with short-term sentiment running high, boosting the overall sector's activity. Strong stocks: 1. GLORY FLAME: up 66.67%, recent market optimism about its business prospects has driven a significant rise in its stock price. 2. FINSOFT FIN: up 36.00%, noticeable capital inflow, with active participation from short-term traders pushing the stock price higher. 3. SV VISION: up 22.45%, increased market expectations for its new products have attracted investor attention. 4. ALCO HOLDINGS: up 18.18%, active short-term capital has made this stock stand out, with optimistic market sentiment. 5. SHANGSHAN GOLD: up 16.67%, benefiting significantly from rising gold prices, attracting considerable buying interest. 6. FANGZHOU JIANKE: up 16.47%, the ongoing heat in the health industry has driven the stock's rise

HK Stock Alerts

HMVOD

GLORY FLAME

FINSOFT FIN

SV VISION

ALCO HOLDINGS

SHANGSHAN GOLD

DRINDA

INSILICO

PAK TAK INT'L

Hong Kong Stock Movement Quick Report: Video and Financial Sectors Strongly Rebound, HMVOD Soars 76% Leading the Market

00100

02039

The Hong Kong stock market showed a mixed performance at midday, with the Hang Seng Index slightly up by 0.2%, while the Technology and State-Owned Enterprise indices retreated, reflecting the continuation of a high-level oscillation pattern. The internet content sector declined during the session. The retail sector was mixed, with Alibaba -W down by 1.78%. The AI and innovative technology sectors were highlighted, with stocks like FANGZHOU JIANKE and MINIMAX-WP surging during the session, indicating a clear rotation in the market structure. At the macro level, fluctuations in external capital and consumer confidence remain the core variables of concern for the market

- The Hong Kong stock market showed mixed performance, with the Hang Seng Index slightly up at 26,830.23 points, while the Hang Seng Tech Index fell by 1.32% to 5,453.46 points.  
- Major internet companies like Tencent, Kuaishou, and Baidu experienced declines, indicating market skepticism in the sector, while retail stocks saw internal fund movements despite some varied performances.  
- Several stocks, including Ark Health and Jun Da, surged due to increased investor interest in high-growth companies, highlighting the ongoing focus on innovation in the AI and technology sectors.

Market Pulse

MINIMAX-W

CIMC

KUAISHOU-W

BIDU-SW

Alibaba

JD-SW

MNSO

SMIC

MEITUAN

Hang Seng Index

Hong Kong Stock Midday Review | The Hang Seng Index slightly rises during the session, with active Internet and AI concepts; FANGZHOU JIANKE rises over 16%

FANGZHOU JIANKE(06086.HK)